{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T19:37:59Z","timestamp":1771011479852,"version":"3.50.1"},"reference-count":58,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although the therapy of chronic lymphocytic leukemia (CLL) has changed rapidly over the last 5 years, the key considerations in selecting a therapy for a previously treated patient with CLL continue to include the nature of the prior therapy and the duration of prior remission to that therapy, the prognostic features of the disease, and the health and comorbidities of the patient in question. For patients treated initially with chemoimmunotherapy, randomized trials have demonstrated the benefit of targeted therapy. Retrospective data suggest that ibrutinib is preferred as a first kinase inhibitor, whereas recent data with venetoclax and rituximab may challenge the choice of ibrutinib as a first novel agent in the relapsed setting. Data on sequencing of novel agents remain quite sparse, consisting of 1 prospective trial that demonstrated the efficacy of venetoclax in patients who have experienced progression with a kinase inhibitor, as well as a retrospective real-world analysis supporting this observation. Novel agents in advanced clinical development include primarily next-generation Bruton\u2019s tyrosine kinase and phosphatidylinositol 3-kinase \u03b4 inhibitors, with other classes still in phase 1 trials. Clinical trials of combination time-limited therapies with the goal of deep remission and discontinuation are also in progress.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.248","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:59Z","timestamp":1555452839000},"page":"248-255","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Relapsed CLL: sequencing, combinations, and novel agents"],"prefix":"10.1182","volume":"2018","author":[{"given":"Jennifer R.","family":"Brown","sequence":"first","affiliation":[{"name":"CLL Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"1","key":"2019111520434074700_B1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"17","key":"2019111520434074700_B2","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O\u2019Brien","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2019111520434074700_B3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"suppl","key":"2019111520434074700_B4","article-title":"Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): up to four years follow-up of the RESONATE study [abstract]","volume":"35","author":"Byrd","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111520434074700_B5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2019111520434074700_B6","article-title":"Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes [abstract]","volume":"101","author":"Jones","year":"2016","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2019111520434074700_B7","article-title":"Randomized trial of ibrutinib versus ibrutinib plus rituximab (Ib+R) in patients with chronic lymphocytic leukemia (CLL) [abstract]","volume":"130","author":"Burger","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2019111520434074700_B8","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2019111520434074700_B9","article-title":"Initial results of a phase Ib study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]","volume":"130","author":"Davids","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111520434074700_B10","article-title":"Acalabrutinib with obinutuzumab in relapsed\/refractory and treatment-naive patients with chronic lymphocytic leukemia: the phase 1b\/2 ACE-CL-003 study [abstract]","volume":"130","author":"Woyach","year":"2017","journal-title":"Blood"},{"issue":"suppl 2","key":"2019111520434074700_B11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/hon.2437_100","article-title":"Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: results of the GENUINE phase 3 study","volume":"35","author":"Sharman","year":"2017","journal-title":"Hematol Oncol"},{"issue":"2","key":"2019111520434074700_B12","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl","key":"2019111520434074700_B13","article-title":"Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL): a 2-year follow-up of the HELIOS study [abstract]","volume":"34","author":"Fraser","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111520434074700_B14","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111520434074700_B15","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2019111520434074700_B16","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2019111520434074700_B17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"2019111520434074700_B18","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.330.330","article-title":"Second interim analysis of a phase 3 study of idelalisib (ZYDELIG\u00ae) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors [abstract]","volume":"124","author":"Sharman","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2019111520434074700_B19","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"issue":"3","key":"2019111520434074700_B20","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(16)30671-4","article-title":"Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial","volume":"18","author":"Zelenetz","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10","key":"2019111520434074700_B21","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111520434074700_B22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2019111520434074700_B23","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"2019111520434074700_B24","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3324\/haematol.10720","article-title":"Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival","volume":"92","author":"Stilgenbauer","year":"2007","journal-title":"Haematologica"},{"issue":"13","key":"2019111520434074700_B25","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111520434074700_B26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"13","key":"2019111520434074700_B27","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2019111520434074700_B28","article-title":"Analysis of PET-CT to identify Richter\u2019s transformation in 167 patients with disease progression following kinase inhibitor therapy [abstract]","volume":"130","author":"Mato","year":"2017","journal-title":"Blood"},{"issue":"15","key":"2019111520434074700_B29","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2019111520434074700_B30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"issue":"22","key":"2019111520434074700_B31","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3230.3230","article-title":"Pooled multi-trial analysis of venetoclax efficacy in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]","volume":"128","author":"Roberts","year":"2016","journal-title":"Blood"},{"issue":"21","key":"2019111520434074700_B32","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.3335.3335","article-title":"Clinical activity of duvelisib (IPI-145), a phosphoinositide-3-kinase-\u03b4,\u03b3 inhibitor, in patients previously treated with ibrutinib [abstract]","volume":"124","author":"Porcu","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2019111520434074700_B33","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1182\/blood-2018-01-826008","article-title":"High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies","volume":"132","author":"Dreger","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2019111520434074700_B34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2018-01-785998","article-title":"How and when I do allogeneic transplant in CLL","volume":"132","author":"Gribben","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2019111520434074700_B35","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"18","key":"2019111520434074700_B36","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience","volume":"128","author":"Mato","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111520434074700_B37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"2019111520434074700_B38","first-page":"498","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated results from the phase 1\/2 ACE-CL-001 study","volume":"130","author":"Byrd","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2019111520434074700_B39","article-title":"Twice daily dosing with the highly specific BTK inhibitor, Bgb-3111, achieves complete and continuous BTK occupancy in lymph nodes, and is associated with durable responses in patients (pts) with chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL) [abstract]","volume":"128","author":"Tam","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2019111520434074700_B40","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111520434074700_B41","article-title":"Results from the phase 3 DUO trial: a randomized comparison of duvelisib vs ofatumumab in patients with relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma [abstract]","volume":"130","author":"Flinn","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2019111520434074700_B42","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","article-title":"PI3K\u03b4-selective and PI3K\u03b1\/\u03b4-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"2019111520434074700_B43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2016-08-731240","article-title":"Silencing c-Myc translation as a therapeutic strategy through targeting PI3K\u03b4 and CK1\u03b5 in hematological malignancies","volume":"129","author":"Deng","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2019111520434074700_B44","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood-2017-05-786947","article-title":"Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia","volume":"131","author":"Janovska","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2019111520434074700_B45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2019111520434074700_B46","article-title":"An integrated safety analysis of the next generation PI3K\u03b4 inhibitor umbralisib (TGR-1202) in patients with relapsed\/refractory lymphoid malignancies [abstract]","volume":"130","author":"Davids","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2019111520434074700_B47","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3225.3225","article-title":"Updated results on the clinical activity of entospletinib (GS-9973), a selective Syk inhibitor, in patients with CLL previously treated with an inhibitor of the B-cell receptor signaling pathway [abstract]","volume":"128","author":"Sharman","year":"2016","journal-title":"Blood"},{"issue":"9","key":"2019111520434074700_B48","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-16-1662","article-title":"The dual Syk\/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia","volume":"23","author":"Blunt","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111520434074700_B49","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.18632\/oncotarget.14588","article-title":"Dual SYK\/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment","volume":"8","author":"Guo","year":"2017","journal-title":"Oncotarget"},{"issue":"suppl 2","key":"2019111520434074700_B50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/hon.2437_61","article-title":"The dual SYK\/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed \/ refractory B cell malignancies","volume":"35","author":"Hamlin","year":"2017","journal-title":"Hematol Oncol"},{"issue":"16","key":"2019111520434074700_B51","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","article-title":"Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia","volume":"21","author":"Cervantes-Gomez","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2019111520434074700_B52","article-title":"Combined venetoclax and ibrutinib for patients with previously untreated high-risk CLL, and relapsed\/refractory CLL: a phase II trial [abstract]","volume":"130","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2019111520434074700_B53","article-title":"Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy [abstract]","volume":"130","author":"Hillmen","year":"2017","journal-title":"Blood"},{"key":"2019111520434074700_B54","article-title":"Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia [published online ahead of print 15 August 2018]","author":"Rogers","journal-title":"Blood"},{"issue":"suppl 2","key":"2019111520434074700_B55","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hon.2437_39","article-title":"Updated results of a multicenter phase 1\/1b study of TGR-1202 in combination with ibrutinib in patients with relapsed or refractory MCL or CLL","volume":"35","author":"Davids","year":"2017","journal-title":"Hematol Oncol"},{"issue":"suppl 2","key":"2019111520434074700_B56","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hon.2437_101","article-title":"Chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib is well tolerated and highly active in patients with advanced CLL and NHL","volume":"35","author":"Nastoupil","year":"2017","journal-title":"Hematol Oncol"},{"issue":"20","key":"2019111520434074700_B57","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","article-title":"Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL","volume":"127","author":"Barr","year":"2016","journal-title":"Blood"},{"issue":"15","key":"2019111520434074700_B58","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.31554","article-title":"Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib","volume":"124","author":"Gordon","year":"2018","journal-title":"Cancer"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/248\/1253941\/hem01834.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/248\/1253941\/hem01834.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,6]],"date-time":"2020-12-06T15:12:28Z","timestamp":1607267548000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/248\/277592\/Relapsed-CLL-sequencing-combinations-and-novel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.248","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}